posted on 2020-05-28, 13:05authored byChristina Spry, Leanne Barnard, Michélle Kok, Andrew K. Powell, Darvina Mahesh, Erick T. Tjhin, Kevin J. Saliba, Erick Strauss, Marianne de Villiers
Pantothenamides
(PanAms) are potent antiplasmodials with low human toxicity currently
being investigated as antimalarials with a novel mode of action. These
structural analogues of pantothenate, the vitamin precursor of the
essential cofactor coenzyme A, are susceptible to degradation by pantetheinase
enzymes present in serum. We previously discovered that α-methylation
of the β-alanine moiety of PanAms increases their stability
in serum and identified N-phenethyl-α-methyl-pantothenamide
as a pantetheinase-resistant PanAm with potent, on-target, and selective
antiplasmodial activity. In this study, we performed structure–activity
relationship investigations to establish whether stability and potency
can be improved further through alternative modification of the scissile
amide bond and through substitution/modification of the phenyl ring.
Additionally, for the first time, the importance of the stereochemistry
of the α-methyl group was evaluated in terms of stability versus
potency. Our results demonstrate that α-methylation remains
the superior choice for amide modification, and that while monofluoro-substitution
of the phenyl ring (that often improves ADME properties) was tolerated, N-phenethyl-α-methyl-pantothenamide remains the most
potent analogue. We show that the 2S,2′R-diastereomer is far more potent than the 2R,2′R-diastereomer and that this cannot be
attributed to preferential metabolic activation by pantothenate kinase,
the first enzyme of the coenzyme A biosynthesis pathway. Unexpectedly,
the more potent 2S,2′R-diastereomer
is also more prone to pantetheinase-mediated degradation. Finally,
the results of in vitro studies to assess permeability
and metabolic stability of the 2S,2′R-diastereomer suggested species-dependent degradation via
amide hydrolysis. Our study provides important information for the
continued development of PanAm-based antimalarials.